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Abstract
Dysphagia is a common symptom in neurodegenerative disorders and is generally associated with increasedmortality. In the clinical
care setting of ataxia patients, no systematical and standardized assessment of dysphagia is employed. Its impact on patients’ health-
related quality of life is not well understood. To assess the impact of dysphagia in ataxia patients on diet, body weight, and health-
related quality of life. We conducted a large survey using self-reported questionnaires for swallowing-related quality of life (Swal-
QOL) and a food frequency list in combination with retrospective clinical data of 119 patients with cerebellar ataxia treated in the
neurological outpatient clinic of a large German university hospital. Seventeen percent of ataxia patients suffered from dysphagia
based on the Swal-QOL score. Less than 1% of all patients reported dysphagia as one of their most disabling symptoms. Dysphagia
was associated with unintentional weight loss (p = 0.02) and reduced health-related quality of life (p = 0.01) but did not affect
individual nutritional habits (p > 0.05; Chi-squared test). Dysphagia is a relevant symptom in cerebellar ataxia. A systematic
screening for dysphagia in patients with cerebellar ataxia would be desirable to enable early diagnosis and treatment.
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Introduction
Dysphagia is a common symptom in patients suffering from
neurodegenerative disorders that affect motor control. In ataxia
disorders, studies on prevalence, consequences, and prognostic
implications of dysphagia are scarce. Cerebellar ataxia arises
from different etiologies, classified as hereditary or sporadic.
For spinocerebellar ataxia (SCA), the reported prevalence of
dysphagia varies considerably from 6 to 74%, depending on
several factors including the underlying genetic mutation with
lower prevalence in pure cerebellar syndromes, e.g., in SCA 6
[1–5].
Symptoms in cerebellar ataxia comprise gait unsteadiness,
limb ataxia, dysarthria, dizziness, and dysphagia [6]. While gait
and speech disorders in chronic disease are known to deteriorate
health-related quality of life (HRQOL) [7, 8], a link between
dysphagia and HRQOL has not been investigated yet.
Neurogenic dysphagia impedes food consumption and may lead
to weight loss, malnutrition, and dehydration [4, 9, 10]. More
drastically, it may cause life-threatening aspiration and pneumo-
nia with increased morbidity and mortality [8, 11, 12]. A post
mortem pathologic study reported neurodegeneration of the
brainstem nuclei to be involved in ingestion as well as aspiration
pneumonia to be the major cause of death in patients suffering
fromSCA-3 [13]. In SCA, every phase of the swallowing process
(lingual, pharyngeal, and esophageal phase) can be impaired [14].
Reduced quality of life accompanies the progression of
chronic neurological diseases, but it remains unclear which
factors determine the individual quality of life in ataxia pa-
tients [7, 15].
To prevent complications, early detection of swallowing dis-
orders is important. Furthermore, identification of influencing
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factors on HRQOL is crucial for individualized and specific
treatment. It remains unclear if swallowing disorders in cerebel-
lar ataxia affect patients’ nutritional habits and are related to
complications such as weight loss and lower body weight.
To discern factors influencing HRQOL and dysphagia-
related consequences in daily life, we conducted a written
survey in a clinically well-characterized large patient cohort
suffering from progressive cerebellar ataxia of various origins.
To screen for swallowing deficits and their influence on qual-
ity of life, we used the Swal-QOL, a validated, wildly used,
subjective assessment tool [16]. The food-frequency list (FFL)
was used to assess individual nutritional habits [17].
Materials and Methods
Study Design and Patients
For this cross-sectional observational study, we screened pa-
tients regularly attending the ataxia outpatient clinic of a large
university hospital (Charité-Universitätsmedizin Berlin,
Germany) from November 2011 to April 2014. Inclusion
criteria were progressive ataxia not related to an acute event
as defined by an experienced clinical assessor and willingness
to participate in the study.We excluded patients with dementia
or progressive cognitive decline. During routine clinical care
visits, we assessed clinical parameters and—if indicated—ge-
netic testing. Patients identified by the above-mentioned pro-
cedure (n = 190) received questionnaires and patient informa-
tion together with the written informed consent by regular
mail. Seventy-one percent of the questionnaires were an-
swered and returned (n = 133). After exclusion of datasets
with missing informed consent form (12) and incomplete data
(2), questionnaires with complete Swal-QOLwere included in
the analysis (two excluded).
Table 1 refers to patient characteristics in the study cohort.
We classified ataxia as hereditary, sporadic, or unknown.
Patients suffering from hereditary ataxia had either positive
genetic testing or a family member with genetically confirmed
hereditary ataxia or strong clinical suspicion of hereditary
ataxia based on pedigree, clinical presentation, and exclusion
of other etiologies. Of the hereditary ataxias, 42 were autoso-
mal dominant (28 patients with SCA 1–3, SCA 6, or SCA 17;
12 patients with SCA 11, 14, 27, or 28; two patients with
Episodic Ataxia type 2 (EA2)), three recessive (one patient
with ataxia telangiectasia and two patients classified as
recessive according to pedigree analysis), and one
mitochondrial ataxia. Among the sporadic ataxias, diagnosis
of sporadic ataxia with onset in adulthood (SAOA) was
established for 33 patients and criteria for multiple system
atrophy with predominant cerebellar ataxia (MSA-C) were
fulfilled in nine patients [18]. Other causes were autoimmune
(n = 9) and toxic related to alcohol abuse (n = 6). In 16 patients
classified as unknown, genetic testing for SCA 1–3, SCA 6,
and Friedreich’s ataxia was negative and clinical signs for
autonomic dysfunction were missing.
The local ethics committee at Charité-Universitätsmedizin
Berlin (EA1/185/13) approved the study and it was conducted
according to the 1964 Helsinki declaration in its currently
applicable version. All participants gave written informed
consent as described above.
General Design of the Survey
The survey included general questions about age, gender,
body weight, and height. Patients were asked to name their
most impairing symptoms and the age, when first symptoms
were noticed [19]. A 5-point Likert scale assessed mobility,
rating the maximal walking distance (if needed with the help
of two persons): 0: < 200 m, 1: < 500 m, 2: < 1 km, 3: < 5 km,
4: > 5 km. To assess potential weight loss, patients reported if
and how much weight they had lost in the past 12 months, if it
had been unwanted (yes/no), if the patient had experienced
reduced appetite (yes/no), and if the amount of food intake
had been reduced in the last 12 months (yes/no). Ongoing
therapy was defined by the time spent with physical, speech,
and occupational therapies weekly. To assess overall impact of
disease on quality of life, patients should report impairment of
their subjective quality of life by the disease on an 11-point
Likert scale: 0: strong impairment and 10: no impairment at
all. To control for unspecific effects of pathologic fatigue and
depressive symptoms, the self-reported Fatigue Severity
Score (FSS, a score > 5 indicating pathologic fatigue) and
Becks Depression Inventory (BDI-II, scores between 14 and
19 indicating mild, 20–28 indicating moderate, and above 29
indicating severe depression) were included in the question-
naire [20, 21].
Assessment of Dysphagia
The swallowing quality of life questionnaire (Swal-QOL) was
used to assess dysphagia and related quality of life (QOL)
using a validated German version of the questionnaire [16,
22, 23]. The Swal-QOL is a reliable and valid self-
assessment tool covering all WHO ICF domains [24]. It com-
prises 44 items assessing 10 swallowing-related QOL do-
mains: food selection, burden, mental health, social function-
ing, fear, eating duration, eating desire, communication, sleep,
and fatigue. Additionally, 14 items focus on symptoms related
to swallowing deficits; three questions evaluate nutritional
intake (presence of percutaneous endoscopic gastrostomy
(PEG) (yes/no), food, and liquid consistency) and one ques-
tion addresses general health. Each item is rated on a 5-point
Likert scale. After linear transformation, domain scores and a
total score from 0 to 100 (100 indicating the most favorable
state) are calculated. We used a seven-domain total score to
438 Cerebellum (2020) 19:437–445
identify patients with swallowing difficulties (scoring below
70). It comprises the first seven domains and reliably reflects
swallowing-related QOL [16, 25]. Patients scoring below 70
are classified as dysphagic throughout the manuscript.
Patients were allowed to fill out the questionnaire with the
help of a proxy, which was reported by four patients (physical
impairment, e.g., limb ataxia). Eleven patients were supported
by a trustworthy person, e.g., a family member.
Assessment of Nutritional Habits
The self-reported Food-Frequency-List (FFL) of the
MONICA project assessed individual nutritional habits, in-
cluding 16 food categories based on the guidelines of the
German Nutrition Society (DGE) [16, 17]. The mean weekly
food intake frequency of, e.g., ‘meat (excluding sausage)’,
‘curds, yoghurt, sour milk’, ‘mineral water’, ‘fresh fruit’,
and others were rated optimal, normal, or unfavorable. The
FFL uses a six-point Likert scale to report frequency ranging
from “almost daily intake” to “never”. Results are rated
according to the method proposed by Winkler and coworkers
[17]: each item is regarded separately, e.g., daily intake of
mineral water is rated optimal whereas daily meat intake is
rated unfavorable. With a maximum score of 32, 14–15 indi-
cates normal food intake while lower scores are regarded as
unfavorable and higher scores as optimal food intake habits.
Data Analysis
We used SPSSVersion 22 (IBMCorp, Armonk, NY, USA) for
data analysis. Figures were created using MATLAB2008b
with Statistics Toolbox Release 2012b (The MathWorks
Inc., Natwick, MA, United States). To test for differences
between dysphagic and non-dysphagic patients regarding di-
agnosis, gender, disease duration, therapies, body weight,
FSS, and BDI-II mean scores, we used Mann-WhitneyU test.
For differences between dysphagic and non-dysphagic pa-
tients regarding weight loss, intention to lose weight, and re-
duction in appetite or food intake, we used Chi-squared test.
For correlation between dysphagia and etiology, age, gender,
Table 1 Overview of patient characteristics
All patients Dysphagic Non-dysphagic MWU
Mean SD Range N Mean SD Range N Mean SD Range N p
Age (years) 58.4 13.3 24–84 117 54.7 12.4 30–74 20 58.8 13.6 24–84 97 0.17
BMI (kg/qm) 25.4 5.1 16–51 117 23.6 5.2 16–34 25.7 5 16–51 0.15
Gender female (n) 59 10 49 0.97
Etiology of ataxia 117 0.35
Hereditary 46 9 37
Sporadic 57 10 45
Unknown 16 1 15
Disease duration (years) 10.9 8.5 1–34 117 9.5 7.1 3–32 10.9 8.5 1–34 0.64
Age of onset (years) 47.4 14.6 4–73 117 45.5 12.5 27–68 47.9 15.1 4–73 0.31
Walking distance [Med; 1–4] 2 2.1 0–4 117 1 1.9 0–4 2 1.9 0–4 0.001
BDI II total score 13.7 9.6 1–4 117 22.3 9.1 1–4 12 8.7 1–4 < 0.001
BDI II classification
1 (minimal) 64 2 61
2 (mild) 27 7 20
3 (moderate) 16 6 9
4 (severe) 12 5 7
FSS mean score 3.7 1.7 0–1 117 4.8 1.5 0–1 3.4 1.6 0–1 0.001
FSS classification
0 (normal) 64 4 58
1 (pathologic) 55 16 39
Physical therapy (min/w) 52 44 0–240 117 69 54 0–240 17 49 40 0–120 70 0.12
Speech therapy (min/w) 23 37 0–120 117 35 33 0–120 13 21 37 0–120 29 0.02
Occupational therapy (min/w) 16 30 0–120 117 28 35 0–120 9 14 29 0–120 22 0.04
Walking distance scale: 0–4; median and variance reported
BDI-II Becks Depression Inventory, FSS Fatigue Severity Scale, MWU Mann-Whitney U test, N number of patients, min/w minutes per week, SD
standard deviation
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disease duration, weight loss, body weight, mobility, quality
of life, fatigue, depression, and nutritional habits, we calculat-
ed Spearman’s correlation coefficient.
We used multiple linear regression analysis to investigate
the association of disease duration, etiology, mobility, FFL,
Swal-QOL, FSS, and BDI-II classification on the variance of
the self-reported QOL scale.
Significance level was established at p < 0.05 and adjusted
for multiple testing for correlation analysis at p = 0.0045.
Results
Dysphagia as Self-reported Main Symptom Versus
Swal-QOL
A single patient reported dysphagia as part of hismost disabling
symptoms. In total, 20 different symptoms were mentioned
(Fig. 1). This patient also reported pain, had a gastric feeding
tube, and suffered from underweight (BMI = 17.6 kg/m2).
Dysphagia was evident in his Swal-QOL total domain score
(14.2) as well. This patient reported symptoms related to saliva
and to pharyngeal but not oral phase in the questionnaire.
Furthermore, more than 75% of all patients reported gait
instability and almost one third reported dysbalance. Each, dys-
arthria, vertigo, and limb weakness were reported by more than
10% of the patients. Patients reporting dysarthria as their most
disabling symptom (n = 26) did not mention additional dyspha-
gia and they did not show reduced body weight (mean BMI =
27 kg/m2 ± 5). Swal-QOL mean domain score in dysarthric
patients was 82.9 ± 18.4 with six patients rated as dysphagic.
Twenty patients presenting significant dysphagia were iden-
tified using a cut-off of 70 in the Swal-QOL total domain score
[16, 25]. For detailed patient characteristics, please refer to
Table 1. Patients with dysphagia more often reported
to regularly attend speech and occupational therapy than those
without. Dysphagic patients were more fatigued and depressed
than patients without dysphagia (U = 1656, p = 0.001 for FSS
and U = 1784, p < 0.001 for BDI-II; compare Table 1).
The Swal-QOL domain score differences between
dysphagic and non-dyphagic patients are shown in Fig. 2.
Scores were significantly different between groups for all do-
mains except sleep (Mann-Whitney U test p < 0.003 for fa-
tigue; p < 0.001 for the remaining domains). Duration of food
intake and social function of eating were most compromised
in the dysphagic group, whereas the desire to eat was less
affected. Patients without dysphagia almost reached the same
score as a healthy control group (Fig. 2c).
The dysphagia phenotype comprised all three phases of
swallowing (pharyngeal, oral, and saliva-related) according
to the 14 Swal-QOL items differentiating dysphagic disorders
(data not shown). Coughing was the most commonly reported
symptom in patients with dysphagia. No different phenotype
was seen in dysphagic patients reporting speech disorders.
High scores on the Swal-QOL were associated with high
mobility levels and high self-reported QOLwhile lower scores
were associated with fatigue and depression. There was a pos-
itive correlation of Swal-QOL total domain score with mobil-
ity (ρ = 0.31, p < 0.001) and QOL (ρ = 0.39, p < 0.001) and a
negative correlation with fatigue (ρ = − 0.39, p < 0.001) and
depression (ρ = − 0.38, p < 0.001). There was no significant
correlation of the Swal-QOL with etiology, age, gender, body
weight, weight loss, disease duration, or nutritional habits.
Fig. 1 Most disabling self-
reported symptoms affecting
quality of life in all patients
(multiple symptoms possible).
Most patients reported gait
instability. Only one patient
reported dysphagia
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Body Weight and Nutrition
Twenty-one patients (seven with dysphagia) reported weight
loss of more than 3 kg in the past 12 months while 14 describ-
ing it as unintentional (Fig. 3c and d). All dysphagic patients
in comparison to half of the non-dysphagic patients stated
their weight loss to be unintentional (χ2 = 5.2, p = 0.02).
There was no difference between groups regarding change
in appetite or reduction of food intake (Fig. 3d).
Dysphagic patients more often reported a reduced food intake
(45%) as compared to non-dysphagic patients (26%; χ2 = 4.2,
p= 0.04) but bodymass index (BMI) was similar in both groups.
According to their BMI, seven patients (four of them with dys-
phagia) were classified as underweight, 49 (seven dysphagic) as
normal weight, and 61 (nine dysphagic) as overweight (Fig. 3a).
Furthermore, no difference in nutritional habits in dysphagic
as compared to non-dysphagic patients was verified among the
116 patients, for which FFL data was available (Fig. 3b). Scores
for all patients ranged from 7 to 24 points with amean of 14.5 ±
3.8. Forty-eight patients (41%) showed favorable, 25 (21%)
normal, and 45 (38%) unfavorable nutritional habits.
Dysphagic patients (n = 20) had a mean score of 13.1 ± 3.8;
non-dysphagic patients (n = 96) had a mean score of 14.8 ± 3.7.
Quality of Life
Dysphagic patients reported significantly lower quality of life
scores (mean = 1.9 ± 2.2) than non-dysphagic patients (mean =
3.3 ± 2.4; U = 839.5, p= 0.01). Multiple linear regression analy-
sis showed that greater mobility and higher Swal-QOL scores
were associated with a higher quality of life (p= 0.00001, F =
13.16, adjusted R2 = 0.18, RMSE= 2.12; Fig. 4). No association
for presence of fatigue or depression, disease duration, etiology,
and nutritional habits (FFL) was seen in the regression analysis.
Discussion and Conclusion
In our cohort, cerebellar ataxia patients hardly reported dys-
phagia as cardinal symptom in contrast to a considerable
(17%) proportion identified as dysphagic by the Swal-QOL.
Dysphagia was linked to unintentional weight loss, whereas
nutritional habit changes did not become apparent. Apart from
the well-established mobility decrease, we also found dyspha-
gia to be associated with a reduced health-related quality of
life (HRQOL) in patients with ataxia.
Among the 20 patients with dysphagia identified by the
Swal-QOL, the only one deliberately reporting dysphagia as
cardinal symptom was a patient with gastric tube and severe
weight loss indicating a late stage of dysphagia. It would be
useful to identify patients with dysphagia earlier, when unin-
tentional weight loss is yet to be prevented. To this end, a
standardized screening in the regular neurological care setting
would be preferable before patients are referred to phoniatric
consultation with videofluoroscopy. The widely varying prev-
alence of dysphagia reported in cerebellar ataxia reflects the
underlying disease pathology and assessment methods. Using
clinical case history, various dysphagia outcome scales, and/or
videofluoroscopy, lower prevalence is being reported in pure
cerebellar ataxia such as SCA 6 with 6–50% as opposed to
complex cerebellar ataxia such as SCA 3 with 64–74% or
Friedreich’s ataxia with up to 100% [1–3, 5, 27, 28].
Videofluoroscopy can detect even subclinical swallowing dif-
ficulties and thus leads to higher prevalence estimates [5].
Systematic evaluation of diagnostic procedures and treatment
is lacking [29].
Additional to clinical examination in combination with clin-
ical case history, a questionnaire such as the Swal-QOLmay be
useful as a screening tool in patients with cerebellar ataxia to
identify dysphagia and its impact on HRQOL, direct patient
care, and further examinations and prevent complications. A
Fig. 2 Swal-QOL domain scores
for seven domains forming the
sum score (a) and the other three
(b). Similar sum score comparing
non-dysphagic and control group
(c; Rinkel et al. [26]; p = 0.06
(t test)), significant differences for
domain scores are marked. Error
bars = standard deviation;
**p < 0.001; *p = 0.003
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questionnaire in comparison to apparatus-assisted examination
is less costly, independent of the clinical setting, better tolerat-
ed, and could guide further complex evaluation, e.g.,
videofluoroscopy to detect silent aspiration [28]. In a recent
study, only 63% of dysphagic patients with Friedreich’s ataxia
could be admitted to further evaluation by videofluorescopy,
illustrating the difficulty of apparatus-assisted diagnostic pro-
cedure for dysphagia in ataxia patients even under study con-
ditions [28]. In that study, dysphagia was evaluated in 60 pa-
tients with Friedreich’s ataxia using standardized oromotor as-
sessment and videofluoroscopy, as compared to mainly late
onset ataxia patients in our study. The authors focused on silent
aspiration, which was found in 34% of patients undergoing
videofluorescopy and was related to repeat-length and two
subscores in oromotor assessment, but could not be predicted
reliably [28].
Aspiration did not seem to affect swallowing-related qual-
ity of life, as no correlation with the Swal-QOL was reported
and only 11 of 60 patients (18%) had a total domain score in
the Swal-QOL below 70, which we used to identify dysphagic
patients. Still, aspiration pneumonia represents one of the ma-
jor factors for a reduced lifespan in hereditary cerebellar ataxia
[13, 30]. The rate of patients experiencing recurrent bronchitis
and pneumonia due to aspiration in a long-term study of 23
patients suffering from different forms of cerebellar ataxia was
up to 50% and 13% of the patients died of aspiration pneu-
monia [31]. Thus, the correct diagnosis and recognition of
dysphagia cannot be underestimated [29]. For detection of
dypshagic symptoms, Swal-QOL and clinical case history
should be considered and the Swal-QOL should be used as
an additional tool to detect impact on HRQOL.
Dysphagia in neurodegenerative diseases such as cerebellar
ataxia, Parkinson’s disease, and Huntington’s disease is known
to cause malnutrition, weight loss, and reduced quality of life,
but can also threaten a patient’s life [4, 8–11]. In Parkinson’s
disease, an impact on quality of life was reported, and in
Huntington’s disease, dysphagia correlated with disease severity
and overall disability [32, 33]. In cerebellar ataxia, we could now
show a correlation with HRQOL, fatigue, depression, and mo-
bility. Disease severity, as rated by walking ability in our cohort,
Fig. 3 Weight (a) and nutrition
(b) in patients. Dysphagic patients
more often show underweight
(a body mass index (BMI) <
18.5 kg/m) and classify weight
loss (c > 3 kg in the last
12 months) as unwanted (d).
dys = dyshagic; non-dys = non-
dysphagic; *p = 0.02
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and Swal-QOL scores were shown to correlate with quality of
life and with each other. Still, reduced mobility or gait instability
were the most reported and most disabling symptoms in our
cohort. Only mobility and dysphagia showed a clear association
with HRQOL. We cannot exclude that a present impairment of
HRQOL affects answers in the Swal-QOL and vice versa. A
negative correlation of Swal-QOL score with fatigue and depres-
sion indices and a significant higher prevalence of pathologic
fatigue and depression in dysphagic patients were seen. We thus
controlled for concurrent presence of pathologic fatigue and de-
pression in the regression analysis. In line with our results, re-
duced well-being linked to dysphagia in Friedreich’s ataxia has
been reported [27]. Furthermore, Swal-QOL total domain score
(including fatigue, sleep, and communication) has been shown to
correlate with disease duration and severity in Friedreich’s ataxia
[28]. We did not find a correlation with disease duration in our
data and results remained unchanged when using the total Swal-
QOL score including the above-mentioned domains. A possible
explanation is the heterogeneity of our cohort with patientsmain-
ly suffering from SCA or sporadic ataxia and not a single patient
suffering from Friedreich’s ataxia. A subgroup analysis for dif-
ferences in dysphagia prevalence and correlations was not feasi-
ble due to small subgroup sizes.
In neurodegenerative disorders, lower body weight and
weight loss have been shown to be correlated with rapid disease
progression and worse functional outcome as well as a decrease
in subjective quality of life [34–36]. Moreover, in children with
ataxia telangiectasia, lower body weight was related to aspiration
as assessed with videofluoroscopy [37]. Though weight loss is
due to multiple factors, among them medication, motor impair-
ment, intestinal factors, metabolic changes, and dysphagia, in our
cohort, we could show unintentional weight loss to mainly occur
in dysphagic ataxia patients. We did not find any differences in
body mass index in dysphagic as compared to non-dysphagic
patients, probably due to the subjective nature of data in a ques-
tionnaire. In line with our results, in a study with a long-term
follow-up, nine of 19 patients with SCA 1 belonging to one
pedigree reported weight loss [38]. Though in adult cerebellar
ataxia, to our knowledge, no relation of weight loss and disease
progression or outcome has been shown so far, unintentional
weight loss and lower body weight in ataxia could be regarded
as a potential risk factor for complications and should thus be
prevented.
Furthermore, a tendency towards less favorable and more un-
favorable nutritional behavior as defined by the German society
for nutrition (DGN) in dysphagic patients was seen in our data.
The relation of dysphagia and change of nutritional habits was
statistically not significant. A larger study would be needed to
confirm or reject this observation. The FFL has not been validat-
ed for patientswith swallowing deficits but is well suited to assess
nutritional habits and their deterioration in general. Still, addition-
al questions concerning aspects of food texture and amount of
food intake would be helpful for a patient population like ours.
In summary, we could show the Swal-QOL to be an addi-
tional useful and simple tool to identify patients with cerebellar
ataxia suffering from dysphagia and rate the impact of dyspha-
gia on subjective quality of life. Dysphagia may be a risk factor
for unintentional weight loss and a tendency towards unfavor-
able nutritional behavior, probably leading to more severe com-
plications such as malnutrition and recurrent infections.
Our work illustrates the necessity of further prospective stud-
ies to investigate the diagnostic work up and impact of correctly
diagnosed dysphagia on disease progression, quality of life, and
its association with disease severity and possible treatments.
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